crizotinib

View Patient Information

An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	MET Tyrosine Kinase Inhibitor PF-02341066
US brand name:	Xalkori
Code name:	PF-2341066 PF02341066
Chemical structure:	(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-Yl)-1h-pyrazol-4-Yl)pyridin-2-amine 2-pyridinamine, 3-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1H-pyrazol-4-yl)-

crizotinib

Search NCI's Drug Dictionary